HLN
Haleon plc
NYSE: HLN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$9.24
-0.65% today
Updated 2026-04-30
Market cap
$42.18B
P/E ratio
18.98
P/S ratio
3.82x
EPS (TTM)
$0.50
Dividend yield
0.74%
52W range
$9 – $11
Volume
8.4M
Haleon plc (HLN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $8.48B | $9.89B | $9.54B | $10.86B | $11.30B | $11.23B | $10.79B |
| Revenue growth (YoY) | — | +16.7% | -3.5% | +13.8% | +4.1% | -0.6% | -4.0% |
| Cost of revenue | $3.68B | $3.98B | $3.60B | $4.28B | $4.34B | $4.29B | $3.80B |
| Gross profit | $4.80B | $5.91B | $5.95B | $6.58B | $6.96B | $6.95B | $6.99B |
| Gross margin | 56.6% | 59.7% | 62.3% | 60.6% | 61.6% | 61.9% | 64.8% |
| R&D | $292.00M | $304.00M | $257.00M | $300.00M | $311.00M | $298.00M | $308.10M |
| SG&A | $3.60B | $4.22B | $1.85B | $2.01B | $2.27B | $4.45B | $4.36B |
| Operating income | $897.00M | $1.60B | $1.64B | $1.82B | $2.00B | $2.21B | $2.42B |
| Operating margin | 10.6% | 16.2% | 17.2% | 16.8% | 17.7% | 19.6% | 22.4% |
| EBITDA | $1.17B | $1.91B | $2.21B | $2.18B | $2.35B | $2.51B | $2.77B |
| EBITDA margin | 13.8% | 19.3% | 23.2% | 20.1% | 20.8% | 22.4% | 25.7% |
| EBIT | $912.00M | $1.61B | $1.94B | $1.90B | $2.04B | $2.32B | $2.42B |
| Interest expense | $28.07M | $25.65M | $16.00M | $347.36M | $414.00M | $394.00M | $332.55M |
| Income tax | $199.00M | $410.00M | $197.00M | $499.00M | $517.00M | $435.00M | — |
| Effective tax rate | 23.3% | 26.4% | 12.4% | 32.0% | 33.0% | 23.2% | 0.0% |
| Net income | $655.00M | $1.15B | $1.39B | $1.06B | $1.05B | $1.44B | $1.63B |
| Net income growth (YoY) | — | +74.8% | +21.4% | -23.7% | -1.0% | +37.5% | +13.1% |
| Profit margin | 7.7% | 11.6% | 14.6% | 9.8% | 9.3% | 12.8% | 15.1% |